Chantibody Therapeutics Inc is a start-up focused on AI-driven, VHH-based biologics for unmet medical needs. We have developed our patented antibody intelligence platform VHHMAb^® for efficient discovery of VHH hits with diversity and quality. Our mission is to develop highly differentiated therapeutics empowered by machine learning, to achieve biological synergy and clinical benefits with multi-specific VHH antibodies. Our lead candidates include (1) CT111 (PD1xCTLA4xVEGF), FIC VHH tri-specific antibody targeting validated IO pathways for pan-tumor indications, (2) CT222 (CD19xBCMAxCD3 TCE), a dual B cell-targeting CD3 T cell engager (TCE) for autoimmune diseases, (3) CT224 (CDH17xCD3 TCE), a FIC biparatopic TCE against a novel tumor-specific target for CRC indication, into clinical trials. We are eager to work with our industrial and financial partners to accelerate therapeutic development and maximize the impact of our innovative products.